Mercernorth9024

The pooled prevalence of malnutrition among hospitalized patients with COVID-19 was 49.11% (95% CI 31.67 to 66.54). The odd of mortality among patients COVID-19 with malnutrition was 10 times more likely as compared to those who were well-nourished.

The prevalence of malnutrition and mortality associated with malnutrition among COVID-19 hospitalized patients was very high which entails a mitigating strategy by different stakeholders to prevent and manage malnutrition and its outcomes.

This systematic review was registered in Prospero's international prospective register of systematic reviews (CRD42020215396).

This systematic review was registered in Prospero's international prospective register of systematic reviews (CRD42020215396).

A comprehensive set of validated core infant and young child feeding (IYCF) indicators replaced the previous guideline and created a consensus on breastfeeding and complementary feeding indicators. It remains unknown how local studies have adopted these originally absent complementary feeding indicators in their data generation. The study is aimed to evaluate the level/rate of adoption of core complementary feeding (CF) indicators in Nigeria.

Meta-analysis of literature on complementary feeding indicators utilized in Nigeria by peer-reviewed articles published from 2009-2019 was conducted. A bibliographic survey was carried out in several databases, review of abstracts and full texts followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Picrotoxin Eligible peer-reviewed published studies were compared to the core CF indicators proposed by WHO in 2008. Data were analysed using SPSS version 25.

A total of 33 articles met the inclusion criteria. Majority (72.7%) of the pdy. Hence, there is need to ensure quick adoption of standard indicators/guidelines by local studies as this will promote the generation of pooled evidence.

Body mass index (BMI) has previously been shown to increase mortality and disease severity in patients with COVID-19, but the pooled effect estimate was heterogeneous. Although BMI is widely used as an indicator, it cannot distinguish visceral from subcutaneous fat. This systematic review and meta-analysis aimed to investigate the association between visceral adiposity, subcutaneous fat, and severe COVID-19.

We performed a systematic literature search using the databases PubMed, Embase, and EuropePMC. Data on visceral fat area (VTA), subcutaneous fat area (SFA), and total fat area (TFA) were collected. The outcome of interest was severe COVID-19. We used a REML random-effects model to pool the mean differences and odds ratio (OR).

There were 5 studies comprising of 539 patients. Patients with severe COVID-19 have a higher VTA (mean difference 41.7cm

[27.0, 56.4], p<0.001; I

0%) and TFA (mean difference 64.6cm

[26.2, 103.1], p=0.001; I

0%). There was no significant difference in terms of SFA between patients with severe and non-severe COVID-19 (mean difference 9.3cm

[-4.9, 23.4], p=0.199; I

1.2%). Pooled ORs showed that VTA was associated with severe COVID-19 (OR 1.9 [1.1, 2.2], p=0.002; I

49.3%).

Visceral adiposity was associated with increased COVID-19 severity, while subcutaneous adiposity was not.

CRD42020215876.

CRD42020215876.

Patients undergoing major gastrointestinal surgery may be in particular need of nutritional therapy due to potential pre-existing disease-related malnutrition and the impact of surgical procedures. Peripheral parenteral nutrition (PPN), delivered via a peripheral catheter, is aligned with the Enhanced Recovery After Surgery (ERAS) concept of minimally invasive interventions where possible. However, uncertainties regarding perioperative PPN for patients undergoing major gastrointestinal surgery arise, in part, due to lack of clinical guidelines. This paper aims to provide practical guidance on perioperative PPN, within the framework of ERAS.

A panel of surgeons and nurses convened to identify knowledge gaps and share their best practice experience regarding PPN provision for patients undergoing major gastrointestinal surgery. Clinical needs were identified and addressed based on the panel's experience and a narrative review.

Key topics addressed include how PPN can support ERAS nutritional recommendations, identifying gastrointestinal surgery patient subgroups who are likely to benefit from PPN, perioperative timepoints when PPN may be required, and optimizing the delivery of PPN. An algorithm to support the identification and management of patients' perioperative nutritional needs was developed.

This paper aims to assist healthcare providers by addressing best practice questions related to the use of PPN during the critical perioperative period within the ERAS concept. This may facilitate timely nutritional intervention to help improve postoperative clinical outcomes and quality of life for patients undergoing major gastrointestinal surgery.

This paper aims to assist healthcare providers by addressing best practice questions related to the use of PPN during the critical perioperative period within the ERAS concept. This may facilitate timely nutritional intervention to help improve postoperative clinical outcomes and quality of life for patients undergoing major gastrointestinal surgery.

The aim of this meta-analysis was to explore the effects of beta-alanine supplementation on Yo-Yo test performance.

Nine databases were searched to find relevant studies. A random-effects meta-analysis of standardized mean differences (SMD) was performed for data analysis. Subgroup meta-analyses were conducted to explore the effects of beta-alanine supplementation duration on Yo-Yo test performance, and the effects of beta-alanine supplementation on performance only in Yo-Yo level 2 test variants.

Ten study groups were included in the meta-analysis. All studies included athletes as study participants. When considering all available studies, there was no significant difference between the placebo/control and beta-alanine groups (SMD 0.68; 95% confidence interval [CI]-0.30, 1.67). When considering only the studies that used supplementation protocols lasting between 6 and 12 weeks, there was a significant ergogenic effect of beta-alanine (SMD 1.02; 95% CI 0.01, 2.05). When considering only the studies that used the level 2 variants of the Yo-Yo test, there was a significant ergogenic effect of beta-alanine (SMD 1.